EUVIMEDEUVIMED entdecken
Crossref

889 Expanding Non-Muscle Invasive Bladder Cancer Care: Assessment of Patient Outcomes Following the Introduction of Outpatient Transurethral Laser Ablation Service

H Premanandhan, C Hobbs

British Journal of Surgery · 10.07.2026 · 113 (Supplement_6)

DOI: 10.1093/bjs/znag063.754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 10.07.2026. Verfasst von H Premanandhan und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Bladder cancer is the most common urological malignancy, and the 2022 Getting It Right the First-Time report highlighted significant variation in its management across the NHS. Standard treatment for non–muscle-invasive bladder cancer (NMIBC) is transurethral resection of bladder tumour (TURBT), which carries notable perioperative risks, particularly in frail, multi-morbid patients. Transurethral laser ablation (TULA) is a minimally invasive alternative. Our trust implemented an innovative outpatient TULA service to improve access for patients not suitable for conventional surgery. This audit aimed to evaluate the safety, effectiveness and early outcomes of TULA service from its pilot phase to ongoing service.

Method

A retrospective review was undertaken on all patients who underwent outpatient TULA between December 2024 and August 2025. Data collected included patient demographics, frailty status, Charlson Comorbidity Index (CCI), anticoagulation status, pain scores and 30-day complications.

Results

Thirty-seven patients (mean age 82.7 years) underwent 39 outpatient TULA procedures; two were repeat treatments for recurrence. Most patients were male (78%) and highly comorbid, with a mean CCI of 7, reflecting high disease burden and estimated 10-year survival of 0%. Over half (51%) were classified as frail. One-third (32.4%) were on long-term anticoagulants, and 83% underwent TULA without interruption to their anticoagulant. Procedures were well tolerated, with a mean pain score of 2.3/10; only one procedure was abandoned due to discomfort. All patients were discharged the same day. The 30-day complication rate was 10.3%, with no significant adverse events.

Conclusions

TULA is a safe, feasible and well-tolerated providing a cost-effective service that theatre capacity pressures.

Zitieren

APA

Premanandhan, H., & Hobbs, C. (2026). 889 Expanding Non-Muscle Invasive Bladder Cancer Care: Assessment of Patient Outcomes Following the Introduction of Outpatient Transurethral Laser Ablation Service. British Journal of Surgery, 113(Supplement_6). https://doi.org/10.1093/bjs/znag063.754

Vancouver

Premanandhan H, Hobbs C. 889 Expanding Non-Muscle Invasive Bladder Cancer Care: Assessment of Patient Outcomes Following the Introduction of Outpatient Transurethral Laser Ablation Service. British Journal of Surgery. 2026;113(Supplement_6). doi:10.1093/bjs/znag063.754

BibTeX
@article{Premanandhan2026,
  author = {Premanandhan, H and Hobbs, C},
  title = {889 Expanding Non-Muscle Invasive Bladder Cancer Care: Assessment of Patient Outcomes Following the Introduction of Outpatient Transurethral Laser Ablation Service},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_6},
  doi = {10.1093/bjs/znag063.754}
}
Kostenlos starten →